Pfizer and Valneva say Lyme disease vaccine candidate showed more than 70% efficacy but missed a key trial endpoint
The Facts
- Pfizer and Valneva said their Lyme disease vaccine candidate showed more than 70% efficacy in a late-stage trial.
- The trial did not meet its primary statistical endpoint because fewer Lyme disease cases occurred than expected.
- Pfizer said it plans to seek regulatory approval for the vaccine candidate despite the missed endpoint.
- The companies said the vaccine was well tolerated and no safety concerns were identified in the trial analysis.
- There is currently no approved human vaccine for Lyme disease.
- Valneva's shares fell sharply after the trial update.
Context
Why did the trial miss its main goal if the vaccine showed more than 70% efficacy?
The companies said the study did not accrue enough Lyme disease cases to make the primary analysis statistically conclusive, even though the vaccine showed more than 70% efficacy in the results they reported CNBC NBC News Reuters Investing.com France Investing.com India.
What did Pfizer say it will do next?
Pfizer said it plans to seek regulatory approval for the vaccine candidate, which it identified as PF-07307405, based on the trial results CNBC Reuters Boursorama Morningstar.
Why is this vaccine being watched closely?
It could become the first approved human vaccine for Lyme disease, and multiple outlets noted that no approved vaccine is currently available Reuters Hill Euronews English.
The receipts — all 72 sources
Wire services (5)
ReutersSuperhits 97.9 Terre Haute, INPfizer-Valneva Lyme vaccine shows more than 70% efficacy but...
Independent coverage (50)
The Philadelphia InquirerLyme disease vaccine shows 70% efficacy, Pfizer says
Boursier.comValneva : remonte un peu après la chute
Bourse DirectValneva trop lourdement sanctionné ?
zonebourseValneva trop lourdement sanctionné ?
LA TERCERAQué es la enfermedad de Lyme, transmitida por garrapatas, qu...
NewsdayCompanies testing new Lyme disease vaccine to seek federal a...
Head TopicsMixed Results For Lyme Disease Vaccine Hit Valneva Shares
Investing.com FranceValneva s'écroule de -39% : Sanction injuste, rebond de +150...
NotiultiValneva: Caída en Bolsa tras Resultados Negativos en Vacuna ...
The HillPfizer's Lyme disease vaccine candidate shows promising resu...
Wonderwall.comStars with Lyme disease
science.orgNew Lyme disease vaccine offers protection -- but falls shor...
MorningstarHealth Care Up, but Not by Much, Amid Cyclical Rotation -- ...
AllTocWhat did Pfizer's Lyme vaccine show?
New Haven RegisterPfizer to seek FDA approval for Lyme vaccine as CT report sh...
WXYZAsk Dr. Nandi: What does it mean that Pfizer's Lyme vaccine ...
Investing.com IndiaJefferies reiterates Valneva stock Buy rating after Lyme tri...
Investing.com FranceJefferies réitère sa recommandation d'achat sur Valneva aprè...
Yahoo! FinanceValneva SE (0OB3.L) stock price, news, quote and history - Y...
finanzen.atValneva Shares Plunge 36% Over Lyme Vaccine Phase 3 Data
NewserLyme Vaccine Shows Promise, but 'Tricky' Path Lies Ahead
ABC BourseCAC 40: La Bourse de Paris commence la semaine en hausse, le...
LesEchos.frMaladie de Lyme, chikungunya : Valneva accumule les déboires...
Les EchosValneva dévisse en Bourse, des doutes sur une des études dan...
The Wall Street JournalPfizer's Lyme Vaccine Shows Strong Efficacy, but Misses Mark...
www.theepochtimes.comPfizer Says Lyme Vaccine Missed Trial Target, Will Still See...
The HillLyme disease vaccine 70 percent effective: Pfizer
Euronews EspañolVacuna contra la enfermedad de Lyme logra buenos resultados ...
Le Figaro.frLes résultats du vaccin contre Lyme de Valneva et Pfizer déç...
euronewsUn vaccin contre Lyme affiche de bons résultats en essai cli...
QuartzPfizer Lyme vaccine shows 70% efficacy, misses trial goal
El-Balad.comPfizer Reports 70% Efficacy for Lyme Disease Vaccine, Says W...
Europe 1Maladie de Lyme : résultats mitigés d'un vaccin à l'étude, V...
The Boston GlobePfizer's Lyme vaccine shows efficacy, but misses key statist...
Euronews EnglishLyme disease vaccine shows strong results in clinical trial
BFM BourseValneva : À cause de l'échec d'un essai clinique crucial, Va...
SudOuest.frMaladie de Lyme : Pfizer " confiant dans le potentiel d'un v...
Les EchosVALNEVA (EPA:VLA) | Pfizer et Valneva annoncent que le candi...
BoursoramaMaladie de Lyme: résultats mitigés d'un vaccin à l'étude, Va...
TF1 INFOMaladie de Lyme : le vaccin Pfizer-Valneva affiche une effic...
The Anniston StarMixed results for Lyme disease vaccine hit Valneva shares
Bourse DirectValneva : violente chute après les résultats d'une étude pou...
CNBCPfizer to seek FDA approval for Lyme disease vaccine candida...
NASDAQ Stock MarketValneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 T...
ABC BourseValneva s'effondre en Bourse après des résultats contrastés ...
STATPfizer's Lyme vaccine results set up tricky regulatory path
NBC NewsPfizer Lyme vaccine shows more than 70% efficacy but misses ...
Boursier.comValneva : violente chute après les résultats d'une étude pou...
ABC BourseValneva: l'essai de phase 3 du vaccin contre la maladie de L...
ABC BourseValneva coule après une mauvaise nouvelle dans la maladie de...
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.